EPRX Eupraxia Pharmaceuticals Inc.

Fundamentals / CIK 0001581178 / USD

Eupraxia Pharmaceuticals Inc. reported $0 in revenue and a net loss of $38.58M for the fiscal year ended December 31, 2025.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open EPRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

4 fiscal years (2022 to 2025), reported in USD.

$0$0$0-$36.07MFY 2022 Net Income: -$18.49M2022FY 2023 Revenue: $0FY 2023 Net Income: -$28.22M2023FY 2024 Revenue: $0FY 2024 Net Income: -$25.50M2024FY 2025 Revenue: $0FY 2025 Net Income: -$38.58M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 31
Revenue $0 $0 $0 --
Research & Development $21.33M $16.08M $20.36M $13.63M
Total Operating Expenses $38.43M $27.00M $27.85M $17.62M
Operating Income -$38.43M -$27.00M -$27.85M -$17.62M
EBITDA -$38.20M -$26.83M -$27.69M -$17.47M
Interest Income $1.41M $1.16M $863K $432K
Interest Expense $0 $604K $1.17M $983K
Income Before Tax -$38.59M -$25.74M -$28.93M -$18.99M
Income Tax Expense $19K $1.8K $36K $0
Net Income -$38.58M -$25.50M -$28.22M -$18.49M
Basic EPS -$1.03 -$0.76 -$1.17 -$0.96
Diluted EPS -$1.03 -$0.76 -$1.17 -$0.96
Basic Shares Outstanding 40.0M 33.9M 24.1M 19.3M
Diluted Shares Outstanding 40.0M 33.9M 24.1M 19.3M

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

No quarterly income statement rows are available in SEC EDGAR CompanyFacts for EPRX.

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $80.56M $33.10M $19.34M $18.26M
Cash & Short-Term Investments $80.56M $33.10M $19.34M $18.26M
Accounts Receivable, Net $716K $258K $154K --
Total Current Assets $85.10M $34.44M $19.80M $18.59M
Property, Plant & Equipment, Net $834K $358K $410K $443K
Total Non-Current Assets $1.05M $506K $463K $533K
Total Assets $86.15M $34.94M $20.27M $19.12M
Accounts Payable $942K $377K $1.29M $1.81M
Total Current Liabilities $5.63M $3.10M $19.37M $3.06M
Total Non-Current Liabilities $76K $0 $0 $8.86M
Total Liabilities $5.70M $3.10M $19.37M $11.91M
Total Debt (incl. Leases) $154K $72K $53K $102K
Common Stock $195.4M $116.4M $92.91M $71.00M
Retained Earnings -$169.6M -$131.0M -$105.5M -$77.28M
Accumulated Other Comp. Income -$2.04M -$4.16M -$2.71M -$2.79M
Total Stockholders' Equity $82.04M $33.40M $2.22M $7.79M
Total Equity $80.45M $31.84M $892K $7.21M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Cash & Cash Equivalents $80.56M $33.10M $19.34M $18.26M
Cash & Short-Term Investments $80.56M $33.10M $19.34M $18.26M
Accounts Receivable, Net $716K $258K $154K --
Total Current Assets $85.10M $34.44M $19.80M $18.59M
Property, Plant & Equipment, Net $834K $358K $410K $443K
Total Non-Current Assets $1.05M $506K $463K $533K
Total Assets $86.15M $34.94M $20.27M $19.12M
Accounts Payable $942K $377K $1.29M $1.81M
Total Current Liabilities $5.63M $3.10M $19.37M $3.06M
Total Non-Current Liabilities $76K $0 $0 $8.86M
Total Liabilities $5.70M $3.10M $19.37M $11.91M
Total Debt (incl. Leases) $154K $72K $53K $102K
Common Stock $195.4M $116.4M $92.91M $71.00M
Retained Earnings -$169.6M -$131.0M -$105.5M -$77.28M
Accumulated Other Comp. Income -$2.04M -$4.16M -$2.71M -$2.79M
Total Stockholders' Equity $82.04M $33.40M $2.22M $7.79M
Total Equity $80.45M $31.84M $892K $7.21M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 31
Net Income -$38.61M -$25.74M -$28.97M -$18.99M
Depreciation & Amortization $238K $172K $156K $148K
Stock-Based Compensation $8.76M $3.22M $1.41M $1.43M
Change in Receivables -$431K -$101K -$104K $230K
Operating Cash Flow -$28.55M -$29.99M -$20.75M -$14.40M
Investing Cash Flow -$589K -$75K -$73K $9.83M
Common Stock Issued $73.89M $22.85M $15.89M $10.64M
Financing Cash Flow $76.06M $45.78M $21.08M $10.80M
Net Change in Cash $46.92M $15.71M $257K $6.24M

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

No quarterly cash flow statement rows are available in SEC EDGAR CompanyFacts for EPRX.

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 31
Return on Equity (ROE) -47.0% -76.3% -1273.4% -237.5%
Return on Assets (ROA) -44.8% -73.0% -139.3% -96.7%
Current Ratio 15.12x 11.10x 1.02x 6.08x
Quick Ratio 14.44x 10.75x 1.01x 5.97x
Debt to Equity 0.00x 0.00x 0.02x 0.01x

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

No quarterly ratios & growth rows are available in SEC EDGAR CompanyFacts for EPRX.
Source: SEC EDGAR CompanyFacts (CIK 0001581178) · from December 31, 2022 Data through December 31, 2025 · synced Nov 20, 2026, 05:36 UTC · Open in terminal